Search results

Selected filters:

Europe
Valuation

Article type

Topic

Sector

Jurisdictions

77 results found for your search

Sort options
14 November 2019

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms

08 November 2019

Catch up on the most important life sciences IP developments from the past month

Read our most recent monthly round-up for key pharma and biotech IP stories from October 2019

01 November 2019

<em>Unwired Planet</em> and <em>Conversant</em> decisions likely to stand, which leaves Huawei and ZTE with big calls to make

The justices hearing the much-watched UK Supreme Court FRAND licensing appeals did not seem disposed to reverse, but that may not be the end of the story

25 October 2019

GlobalFoundries’ patent attack on TSMC may have come too late  

In-depth analysis shows that the Taiwanese semiconductor business has not only bulked up its portfolio over the last decade, but also considerably improved its quality

25 October 2019

UK Supreme Court hands employee-inventor a dramatic £2 million victory

Judgment vindicates professor’s 20-year fight for share of Unilever licensing profit and looks set to reshape British law on employee compensation for inventions

09 October 2019

IBM has the world's most valuable patent portfolio, new analysis claims

Samsung, Canon, Microsoft and Bosch round-out the top five who, between them, are said to own assets worth well in excess of $35 billion

23 September 2019

Nanjing judge sets Chinese SEP rate in dispute between Conversant and Huawei

Chinese court has had its say on royalties - and it looks like the telecoms giant has got exactly what it was looking for

26 August 2019

Three key IP takeaways from Bayer's $7.6 billion sale of its animal health unit

The German company's divestiture to Elanco is the latest example of a pharma giant fleeing non-core business areas - and it is unlikely to be the last

19 July 2019

Alphabet is trimming down its portfolio - but only after sustained growth  

The tech giant saw a steep drop in the number of US patents granted in 2018 after having spent years building its portfolio organically and through strategic acquisitions

16 July 2019

Gilead’s unique $5.1 billion licensing deal shows the range of IP monetisation options open to biotech sector

New boss explains that the Big Pharma company will seek out “diverse and creative” asset partnerships – rather than large acquisitions – to boost its pipeline

05 July 2019

Get ready for the first CRISPR patent pool

In an exclusive interview, MPEG LA’s Kristin Neuman says that a pool is on its way despite the UCal v Broad stand-off and talks about the future of licensing in biotech’s ‘golden age’

02 July 2019

AbbVie’s Allergan play designed to mitigate Humira patent cliff

The $63 billion purchase is designed to mitigate the effects of losing the exclusive rights to the world’s best selling drug

13 June 2019

Huawei’s $1 billion Verizon demand: politics or profit?

Ongoing royalty negotiations are revealed after US network operator reportedly notifies government. Why the conflict, which follows a 2016 dispute with T-Mobile, may alarm Nokia and Ericsson

12 June 2019

IAM and sister publication GDR launch major data event

The Data Business Congress will take place in San Jose, CA, next February with the focus on the capture, protection, management, exploitation and monetisation of one of the pivotal assets of the 21st century

07 June 2019

Roche trumps rivals with strongest biotech patent portfolio

Trailing behind the Swiss giant are DowDuPont and Bayer, both of which have seen a drop in the value of their holdings